TY - JOUR
T1 - Molecular mechanisms of arrhythmogenic cardiomyopathy
AU - Austin, Karyn M.
AU - Trembley, Michael A.
AU - Chandler, Stephanie F.
AU - Sanders, Stephen P.
AU - Saffitz, Jeffrey E.
AU - Abrams, Dominic J.
AU - Pu, William T.
N1 - Funding Information:
M.A.T. is supported by the NIH (T32HL07572). D.J.A. is supported by the AHA (16CSA28750006). W.T.P. is supported by the NIH (UG3 HL141798) and the AHA (16CSA28750006) and by charitable donations from the Boston Children’s Heart Center. The Inherited Cardiac Arrhythmia Program (S.F.C., D.J.A. and W.T.P.) is generously supported by the Mannion and Roberts families.
Publisher Copyright:
© 2019, Springer Nature Limited.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Arrhythmogenic cardiomyopathy is a genetic disorder characterized by the risk of life-threatening arrhythmias, myocardial dysfunction and fibrofatty replacement of myocardial tissue. Mutations in genes that encode components of desmosomes, the adhesive junctions that connect cardiomyocytes, are the predominant cause of arrhythmogenic cardiomyopathy and can be identified in about half of patients with the condition. However, the molecular mechanisms leading to myocardial destruction, remodelling and arrhythmic predisposition remain poorly understood. Through the development of animal, induced pluripotent stem cell and other models of disease, advances in our understanding of the pathogenic mechanisms of arrhythmogenic cardiomyopathy over the past decade have brought several signalling pathways into focus. These pathways include canonical and non-canonical WNT signalling, the Hippo–Yes-associated protein (YAP) pathway and transforming growth factor-β signalling. These studies have begun to identify potential therapeutic targets whose modulation has shown promise in preclinical models. In this Review, we summarize and discuss the reported molecular mechanisms underlying the pathogenesis of arrhythmogenic cardiomyopathy.
AB - Arrhythmogenic cardiomyopathy is a genetic disorder characterized by the risk of life-threatening arrhythmias, myocardial dysfunction and fibrofatty replacement of myocardial tissue. Mutations in genes that encode components of desmosomes, the adhesive junctions that connect cardiomyocytes, are the predominant cause of arrhythmogenic cardiomyopathy and can be identified in about half of patients with the condition. However, the molecular mechanisms leading to myocardial destruction, remodelling and arrhythmic predisposition remain poorly understood. Through the development of animal, induced pluripotent stem cell and other models of disease, advances in our understanding of the pathogenic mechanisms of arrhythmogenic cardiomyopathy over the past decade have brought several signalling pathways into focus. These pathways include canonical and non-canonical WNT signalling, the Hippo–Yes-associated protein (YAP) pathway and transforming growth factor-β signalling. These studies have begun to identify potential therapeutic targets whose modulation has shown promise in preclinical models. In this Review, we summarize and discuss the reported molecular mechanisms underlying the pathogenesis of arrhythmogenic cardiomyopathy.
UR - http://www.scopus.com/inward/record.url?scp=85065136570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065136570&partnerID=8YFLogxK
U2 - 10.1038/s41569-019-0200-7
DO - 10.1038/s41569-019-0200-7
M3 - Review article
C2 - 31028357
AN - SCOPUS:85065136570
SN - 1759-5002
VL - 16
SP - 519
EP - 537
JO - Nature Reviews Cardiology
JF - Nature Reviews Cardiology
IS - 9
ER -